OpenAI has added Fast answers to ChatGPT and launched a separate free workspace for verified U.S. clinicians, giving the product two new paths into more routine, high-value use cases.
OpenAI’s latest leadership changes are more than a personnel story. The company is shedding two senior figures tied to science research and video generation just weeks after it said it was cutting back on “side quests,” a sign it is tightening its focus around enterprise AI and core commercial products.
OpenAI released ChatGPT Images 2.0 on April 21, 2026, a significant update to its image generation system that expands support for more complex prompts, broader aspect ratios and a new “thinking” mode. The company is positioning the tool for practical use inside ChatGPT and Codex rather than one-off image generation.
OpenAI on April 22, 2026, launched ChatGPT for Clinicians, a free U.S.-only version for verified physicians, nurse practitioners, physician assistants and pharmacists that is aimed at documentation and medical research tasks.
OpenAI is briefing U.S. federal agencies, state governments and Five Eyes allies on GPT-5.4-Cyber, a cybersecurity-focused model it rolled out under tiered access last week. The move widens the company’s push into defensive security work as governments and banks race to test where advanced AI can help find flaws without increasing risk.
OpenAI has introduced ChatGPT Images 2.0 in ChatGPT, pairing the new image model with a “thinking” mode for paid users that can plan and refine outputs before generating them.
OpenAI has introduced GPT-5.4-Cyber, a variant of its latest flagship model tuned for defensive cybersecurity work, and is limiting access to vetted users through an expanded Trusted Access for Cyber program. The release puts a more capable model in the hands of security teams while keeping distribution tightly controlled.
OpenAI has introduced a Codex-only seat for ChatGPT Enterprise and updated pricing for new workspaces, a small but telling shift that makes AI coding access easier to buy as enterprises tighten how they pay for frontier tools.
OpenAI on April 16 introduced GPT-Rosalind, a frontier reasoning model built for drug discovery, genomics analysis, protein reasoning and other scientific research tasks. The release expands OpenAI’s push beyond general-purpose assistants into specialized workflows where long-context reasoning, data handling and domain-specific analysis can carry direct commercial and research value.
OpenAI is widening Codex from a popular developer tool into a more formal enterprise offering, launching Codex Labs and teaming with large systems integrators to help customers move the product from pilots into production.
